Drugs / KM-819
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03022799 | Nov 2016 → Sep 2017 | Parkinson disease | Kainos Medicine Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05695378 | Feb 2023 → Aug 2024 | multiple system atrophy | Kainos Medicine Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05670782 | Jul 2022 → Oct 2025 | Parkinson disease | FAScinate Therapeutics Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KM-819 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03022799 ↗ |
| Route | Oral | “Multiple Oral Doses of KM-819” NCT03022799 ↗ |